Safety study of Recombinant human C1-INH (rhC1-INH) in pregnant women with hereditary angioedema (HAE )

Trial Profile

Safety study of Recombinant human C1-INH (rhC1-INH) in pregnant women with hereditary angioedema (HAE )

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 New trial record
    • 05 Mar 2018 Results assessing safety of rhC1-INH in pregnant women with HAE, presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top